Syndax Pharmaceuticals' 2024 Financial Update Plans Announced

Author: Hannah Lewis Updated: 02-24-2025 07:07 AM

Syndax Pharmaceuticals to Release 2024 Financial Results

Syndax Pharmaceuticals, a leading commercial-stage biopharmaceutical company dedicated to advancing cancer therapy, recently announced an update regarding its upcoming financial results. The company, known for its innovative cancer treatment pipeline, will report its fourth quarter and overall performance for the year 2024.

Key Details of the Announcement

Scheduled for March 3, 2025, the financial results will be discussed during a live conference call and audio webcast at 8:00 a.m. ET. This session aims to not only highlight the company’s financial performance but also to provide insights into their ongoing business strategies. Participants can tune in to the event from the comfort of their offices or homes.

How to Access the Conference Call

For those interested in joining, the conference call will be easily accessible. Domestic participants can dial in at 800-590-8290, while international attendees can connect at 240-690-8800. The Conference ID designated for the event is Syndax4Q24. Additionally, the audio webcast will also be available online for broader engagement.

Replay Availability

In case you miss the live event, there will be a recording available for listening. The replay will be on Syndax’s official website approximately 24 hours after the call and will be accessible for a duration of 90 days. This allows stakeholders and interested parties the chance to catch up on the details discussed.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is at the forefront of biopharmaceutical development, particularly in the area of oncology. Their robust pipeline features key therapies such as Revuforj (revumenib), an FDA-approved drug recognized for its role as a menin inhibitor. Furthermore, the company is advancing Niktimvo™ (axatilimab-csfr), another FDA-approved monoclonal antibody targeting the colony-stimulating factor 1 (CSF-1) receptor.

Commitment to Innovative Cancer Care

Syndax's mission is underscored by their unwavering commitment to reimagine the way cancer is treated. They are currently conducting several clinical trials aimed at unlocking the full potential of their therapies, demonstrating their dedication to improving patient outcomes.

Get Involved with Syndax

Patients and healthcare professionals can stay informed about Syndax’s progress and upcoming clinical trials by visiting the company’s website. It also offers valuable resources for patients seeking information about their cancer treatments and options available through clinical research.

Follow Syndax on Social Media

For the latest updates and news, you can follow Syndax Pharmaceuticals on various social media platforms, including X and LinkedIn. Engaging with their content on these platforms can provide immediate news, insights, and developments from the company.

Frequently Asked Questions

What is the date of Syndax's financial results announcement?

The financial results will be announced on March 3, 2025.

How can I participate in the conference call?

You can join the call by dialing 800-590-8290 for domestic calls or 240-690-8800 for international calls, using Conference ID: Syndax4Q24.

Where can I find the replay of the conference call?

The replay will be available on the Investors section of Syndax’s website approximately 24 hours after the call.

What are Syndax's key products?

Syndax is developing innovative cancer therapies, including Revuforj (revumenib) and Niktimvo™ (axatilimab-csfr).

How does Syndax support cancer research?

Syndax supports cancer research through clinical trials aimed at improving treatment outcomes for patients with various types of cancer.

About The Author

Hi there, I'm Hannah Lewis, a writer and financial specialist of 36 years old committed to making money understandable and approachable to everyone. Years of working in the field have given me a thorough grasp of market trends, investment techniques, and economic fundamentals. My objective is to enable people, by means of understandable, useful guidance, to take charge of their financial destiny.

I have written many articles for financial blogs over my career that simplify difficult financial ideas into understandable insights. Being financially literate is a critical ability, and I am passionate about enabling people to confidently manage their financial lives. Regardless of your level of experience, my work will help you at every stage of the investment process. I appreciate being allowed to share in your success and financial expansion.

Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.